Status:
COMPLETED
Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®
Lead Sponsor:
Bayer
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months
Eligibility Criteria
Inclusion
- Hypertensive patients seen by the physician requiring antihypertensive treatment
Exclusion
- According to the local drug information
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
2052 Patients enrolled
Trial Details
Trial ID
NCT00927537
Start Date
April 1 2008
End Date
October 1 2011
Last Update
September 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Switzerland